The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosis - Lenk, Lennart; Baccelli, Irène; Laqua, Anna; Heymann, Julia; Reimer, Claas; Dietterle, Anna; Winterberg, Dorothee; Mary, Caroline; Corallo, Frédérique; Taurelle, Julien; Narbeburu, Emma; Neyton, Stéphanie; et al. (Blood, 2024)